Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis

Motoaki Shiratsuchi, Seiichi Motomura, Yasunobu Abe, Satoshi Shiokawa, Junji Nishimura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) characteristically consists of fibrotic changes in various organs, and immunological abnormality is the main cause of the disease. Although high-dose immunosuppressive therapies with autologous or allogeneic hematopoietic stem cell support can reverse the disease course, they have a high treatment-related mortality. We report the successful use of nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for SSc. A 40-year-old woman with diffuse scleroderma and interstitial pneumonia underwent allogeneic peripheral blood stem cell transplantation from an HLA-identical sibling after conditioning with low-dose total-body irradiation and fludarabine. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and mycophenolate mofetil. No infection or acute GVHD developed. One year after transplantation, the patient developed membranous glomerulopathy caused by chronic GVHD that was successfully treated with prednisolone. The patient's skin score decreased dramatically, and her pulmonary function is stable 4 years after transplantation. Nonmyeloablative allogeneic HSCT may be more effective than conventional therapies for SSc.

Original languageEnglish
Pages (from-to)1207-1209
Number of pages3
JournalClinical Rheumatology
Volume27
Issue number9
DOIs
Publication statusPublished - Sep 1 2008

Fingerprint

Systemic Scleroderma
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Transplantation
Mycophenolic Acid
Peripheral Blood Stem Cell Transplantation
Diffuse Scleroderma
Membranous Glomerulonephritis
Whole-Body Irradiation
Interstitial Lung Diseases
Immunosuppressive Agents
Hematopoietic Stem Cells
Prednisolone
Cyclosporine
Siblings
Therapeutics
Lung
Skin
Mortality
Infection

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis. / Shiratsuchi, Motoaki; Motomura, Seiichi; Abe, Yasunobu; Shiokawa, Satoshi; Nishimura, Junji.

In: Clinical Rheumatology, Vol. 27, No. 9, 01.09.2008, p. 1207-1209.

Research output: Contribution to journalArticle

Shiratsuchi, Motoaki ; Motomura, Seiichi ; Abe, Yasunobu ; Shiokawa, Satoshi ; Nishimura, Junji. / Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis. In: Clinical Rheumatology. 2008 ; Vol. 27, No. 9. pp. 1207-1209.
@article{9a4501d1d1874e08b4ef80e56db53f33,
title = "Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis",
abstract = "Systemic sclerosis (SSc) characteristically consists of fibrotic changes in various organs, and immunological abnormality is the main cause of the disease. Although high-dose immunosuppressive therapies with autologous or allogeneic hematopoietic stem cell support can reverse the disease course, they have a high treatment-related mortality. We report the successful use of nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for SSc. A 40-year-old woman with diffuse scleroderma and interstitial pneumonia underwent allogeneic peripheral blood stem cell transplantation from an HLA-identical sibling after conditioning with low-dose total-body irradiation and fludarabine. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and mycophenolate mofetil. No infection or acute GVHD developed. One year after transplantation, the patient developed membranous glomerulopathy caused by chronic GVHD that was successfully treated with prednisolone. The patient's skin score decreased dramatically, and her pulmonary function is stable 4 years after transplantation. Nonmyeloablative allogeneic HSCT may be more effective than conventional therapies for SSc.",
author = "Motoaki Shiratsuchi and Seiichi Motomura and Yasunobu Abe and Satoshi Shiokawa and Junji Nishimura",
year = "2008",
month = "9",
day = "1",
doi = "10.1007/s10067-008-0927-8",
language = "English",
volume = "27",
pages = "1207--1209",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "9",

}

TY - JOUR

T1 - Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis

AU - Shiratsuchi, Motoaki

AU - Motomura, Seiichi

AU - Abe, Yasunobu

AU - Shiokawa, Satoshi

AU - Nishimura, Junji

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Systemic sclerosis (SSc) characteristically consists of fibrotic changes in various organs, and immunological abnormality is the main cause of the disease. Although high-dose immunosuppressive therapies with autologous or allogeneic hematopoietic stem cell support can reverse the disease course, they have a high treatment-related mortality. We report the successful use of nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for SSc. A 40-year-old woman with diffuse scleroderma and interstitial pneumonia underwent allogeneic peripheral blood stem cell transplantation from an HLA-identical sibling after conditioning with low-dose total-body irradiation and fludarabine. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and mycophenolate mofetil. No infection or acute GVHD developed. One year after transplantation, the patient developed membranous glomerulopathy caused by chronic GVHD that was successfully treated with prednisolone. The patient's skin score decreased dramatically, and her pulmonary function is stable 4 years after transplantation. Nonmyeloablative allogeneic HSCT may be more effective than conventional therapies for SSc.

AB - Systemic sclerosis (SSc) characteristically consists of fibrotic changes in various organs, and immunological abnormality is the main cause of the disease. Although high-dose immunosuppressive therapies with autologous or allogeneic hematopoietic stem cell support can reverse the disease course, they have a high treatment-related mortality. We report the successful use of nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for SSc. A 40-year-old woman with diffuse scleroderma and interstitial pneumonia underwent allogeneic peripheral blood stem cell transplantation from an HLA-identical sibling after conditioning with low-dose total-body irradiation and fludarabine. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and mycophenolate mofetil. No infection or acute GVHD developed. One year after transplantation, the patient developed membranous glomerulopathy caused by chronic GVHD that was successfully treated with prednisolone. The patient's skin score decreased dramatically, and her pulmonary function is stable 4 years after transplantation. Nonmyeloablative allogeneic HSCT may be more effective than conventional therapies for SSc.

UR - http://www.scopus.com/inward/record.url?scp=48449101316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48449101316&partnerID=8YFLogxK

U2 - 10.1007/s10067-008-0927-8

DO - 10.1007/s10067-008-0927-8

M3 - Article

C2 - 18483758

AN - SCOPUS:48449101316

VL - 27

SP - 1207

EP - 1209

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 9

ER -